Posted: May 27, 2019 ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a large umbrella trial evaluating patients with early-stage NSCLC who have undergone complete tumor resection. As […] Read more
By Paul A. Bunn Jr., MD Posted: May 27, 2019 It is indeed an exciting time in lung cancer therapeutics, and we have reasons to be optimistic. To put these advances […] Read more
By Anja C. Roden, MD, and Natasha Rekhtman, MD, PhD Posted: May 27, 2019 Dr. Anja C. Roden Pulmonary neuroendocrine tumors are classified according to the World Health Organization into typical […] Read more
By Elizabeth Gore, MD Posted: May 27, 2019 IN REFERENCE TO: De Ruysscher D, Dingemans AC, Praag J, et al. Prophylactic cranial irradiation versus observation in radically treated stage III non-small-cell […] Read more
By Cornedine Jannette de Gooijer, MD; Maria Disselhorst, MD; and Paul Baas, MD, PhD Posted: May 27, 2019 Dr. Cornedine Jannette de Gooijer Until 2015, few changes occurred with respect to […] Read more
Posted: May 27, 2019 In March 2019, another successful Best of the World Lung Cancer Conference (BWLCC) was held in Lima, Peru. This was the fourth year in a row that […] Read more
By Marianne Davies, DNP, RN, ACNP Posted: May 27, 2019 The International Thoracic Oncology Nursing Forum (ITONF) is an independent organization to support nurses who work in lung cancer and mesothelioma […] Read more
Posted: May 27, 2019 Mesothelioma is a rare tumor with limited treatment options. The upcoming IASLC 2019 Mesothelioma Meeting (July 10-12) in New York City—a first of its kind for this […] Read more
By Paul A. Bunn, Jr., MD, FASCO Posted: May 27, 2019 The 19th annual IASLC Targeted Therapies of Lung Cancer Meeting was held in Santa Monica, California, from February 20 to […] Read more
Posted: May 27, 2019 Nasser H. Hanna, MD, is the Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research at Indiana University School of Medicine, and he specializes […] Read more